Kim Soon Bae, Kim Sang Hyun, Chang Jae Won, Lee Sang Koo, Min Won Ki, Chi Hyun Sook, Park Jung Sik
Department of Internal Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea.
Ren Fail. 2004 Jul;26(4):381-4. doi: 10.1081/jdi-120039821.
To evaluate the effects of celecoxib, a cyclooxygenase-2 inhibitor, on the level of high-sensitivity C-reactive protein (hs-CRP), D-dimer, von Willebrand factor (vWF) and troponin-T, 46 chronic peritoneal dialysis (CPD) patients with hs-CRP equal or greater than 0.25 mg/dL were randomized to the treatment group who took 200 mg of celecoxib daily for 4 weeks or to the control group who did not take the medication. The levels of hs-CRP, albumin, D-dimer, vWF and troponin-T were measured at baseline and at 4 weeks of the study. Baseline values of all the parameters were not significantly different between the two groups. In the control group, the levels of hs-CRP, albumin, D-dimer, vWF and troponin-T did not change. In the treatment group, administration of celecoxib for 4 weeks significantly reduced hs-CRP from median 0.77 (range 0.25-7.08) to 0.39 mg/dL (range 0.11-5.22, p<0.05). The levels of albumin, D-dimer, vWF and troponin-T levels were not affected by the administration of celecoxib. These results showed that celecoxib had an antiinflammatory effect in usual dosage in CPD patients.